Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
Spero Therapeutics Stock
Spero Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Esther Rajavelu
- Employees
- 25
- Market cap
- $67 M
- IPO
- 02/11/2017
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key…
Spero Therapeutics stock: price history
1D
-2.5%
1W
-3.4%
1M
+1.8%
6M
-58.6%
YTD
-50.6%
1Y
-49.8%
2Y
-8.0%
5Y
-93.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~21% weaker price swings than usual
Ask the agents about Spero Therapeutics
Analyst assessment of Spero Therapeutics
0
STRONG BUY
6
BUY
5
HOLD
2
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 14/09/2026
Spero Therapeutics stock metrics
P/E
8.21
P/B
1.51
EV/EBITDA
2.32
RETURN ON EQUITY
-21.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.1%
FLOAT SHARES
46,382,570
AVG. DAILY VOLUME (30D)
714,793
Insider transactions (SEC)
Zack Debra
Jackson Scott Thomas
THOMAS FRANK E
VINK PATRICK V.J.J.
Pottage John C Jr
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Spero Therapeutics stock
What does Spero Therapeutics do?
Spero Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Esther Rajavelu, the company employs around 25 people.
The IPO was on 02/11/2017; the stock trades on NASDAQ under the ticker SPRO.
What do analysts say about Spero Therapeutics stock?
13 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
This is an external assessment, not a statement by Market Jury.
When does Spero Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Spero Therapeutics pay a dividend?
Yes. The last dividend was US$0.02 per share, ex-date 16/09/2015, paid on 07/10/2015.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Spero Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Spero Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Spero Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.